Low densities of serotonin and peptide yy cells in the colon of patients with irritable bowel syndrome

Digestive Diseases and Sciences

Volumn 57, Issue 4, 2012, Pages 873-878

  El Salhy, M ^a,b   Gundersen, D ^c   Ostgaard H ^a,b   Lomholt Beck, B ^d   Hatlebakk, J G ^b   Hausken, T ^b  

^a Department of Medicine   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Helse Fonna ^*  (Norway)

^d Haugesund Helse Fonna Hospital   (Norway)

Author keywords

Colon; Computer image analysis; IBS; Immunohistochemistry; PYY; Serotonin

Indexed keywords

OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; SEROTONIN;

ADULT; ARTICLE; CELL DENSITY; CLINICAL ARTICLE; COLON; COLONOSCOPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IRRITABLE COLON; MALE; PRIORITY JOURNAL; SOMATOSTATIN CELL;

EID: 84864041929     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1948-8     Document Type: Article

References (46)

1. Thompson WG. A world view of IBS. In Camilleri M, Spiller R, eds. Irritable bowel syndrome: diagnosis and treatment. Philadelphia and London: Saunders: 2002:17-26.
2. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569-1580.
3. HuginAP,Whonwell PJ, Tack J,Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40, 000 subjects. Alment Pharmacol Ther. 2003;17:643-650.
4. Wilson S, Roberts L, Roalfe A, Bridge P, Sukhdev S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract. 2004;54:495-502.
5. Whitehead WE, Burnett CK, Cook EW, III, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-2253.
6. Everhart JE, Renault PF. Irritable bowel syndrome in officebased practice in the United States. Gastroenterology. 1991;100: 998-1005.
7. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet. 1983;1:632-634.
8. Whorwell PJ, Clouter C, Smith CL. Oesophagus motility in the irritable bowel syndrome. BMJ. 1981;282:1101-1102.
9. Caballero-Plasencia AM, Valenzula-Barranco M, Herrerias-Gutierrez JM, et al. Altered gastric emptying in patients with irritable bowel syndrome. Eur Nul Med. 1999;26:404-409.
10. Evans PR, Bak YT, Shuter B, et al. Gastroparesis and small bowel dysmotility in irritable bowel syndrome. Dig Dis Sci. 1997; 42:2087-2093.
11. van Wijk HJ, Smout AJ, Akkerman LM, et al. Gastric emptying and dyspeptic symptoms in irritable bowel syndrome. Scand J Gastroenterol. 1992;27:99-102.
12. Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome: relation of disorders in the transit of single solid meal top symptom patterns. Gut. 1983;24:405-411.
13. Kellow JE, Philips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987;92:1885-1893.
14. Kellow JE, Philips SF, Miller LJ, et al. Dysmotility of the small bowel in irritable bowel syndrome. Gut. 1988;29:1236-1243.
15. El-Salhy M. Gut neuroendocrine system in diabetes gastroenteropathy: possible role in pathophysiology and clinical implications. In Ford AM, ed. Focus on diabetes mellitus research. New York: Nova Science Publishers; 2006:79-102.
16. Lee KJ, Kim YB, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell and lamnia propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2008;23:1689-1694.
17. Wang SH, Dong L, Luo JY, et al. Decreased expression of serotonin in the jejenum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol. 2007;13:6041-6047.
18. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut. 2000;47:811-904.
19. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125:1651-1659.
20. Park JH, Rhee P-L, Kim G, et al. Enteroendocrine cell counts correlated with visceral hypersensitivity in patients with diarrhoea- predominant irritable bowel syndrome. Neurogastroenterol Motil. 2006;18:539-546.
21. Van Der Veek PP, Biemond I, Masclee AA. Proximal and distal gut hormone secretion in irritable bowel syndrome. Scand J Gastroenterol. 2006;41:170-177.
22. Dizdar V, Spiller R, Hanevik K, Gilja OH, El-Salhy M, Hausken T. Relative importance of CCK (cholecystokinin) and 5-HT (serotonin) in Giardia-induced Post-infectious IBS. Aliment Pharmacol Ther. 2010;31:883-891.
23. El-Salhy M, Vaali K, Dizdar V, Hausken T (2010) Abnormal small intestinal endocrine cells in patients with irritable bowel syndrome. Dig. Dig. Sci. (Epub ahead of print). doi:10.1007/s10620-010- 1169-6.
24. El-Salhy M, Lomholt-Beck B, Hausken T (2010) Chromogranin as a tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol. (Epub ahead of print). doi:10.3109/00365521. 2010.503965.
25. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
26. http://www.romecriteria.org.
27. El-Salhy M, Stenling R, Grimelius L. Peptidergic innervation and endocrine cells in the human liver. Scand J Gastroenterol. 1993; 28:809-815.
28. Sandström O, El-Salhy M. Aging and endocrine cells of human duodenum. Mech Ageing Develop. 1999;108:39-48.
29. Sandström O, El-Salhy M. Human rectal endocrine cells and aging. Mech Ageing Develop. 1999;108:219-226.
30. Sjölund K, Sandèn G, Håkanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology. 1983;85:1120-1130.
31. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004;126:1657-1664.
32. Spiller RC, Jenkins D, Thornely JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Camylobacter enteritis and in postdysentric irritable bowel syndrome. Gut. 2000;47:804-811.
33. Lee HS, Lim JH, Park H, Lee SI. Increased immunoreactive cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection-an observation in a small case control study. Yonsei Med J. 2009;51:45-51.
34. Camilleri M. Is there a SERT-ain association with IBS. Gut. 2004;53:1396-1398.
35. Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut. 2004;53:1452-1458.
36. Chey D, Nojkov B, Rubenstein JH, Dobhan RR, Greensen JK, Cash BD. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105:859-865.
37. Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? Pediatr Gastroenterol Nutr 2007;45: S115-S119.
38. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010;161:19-27.
39. Yang GB, Lackner AA. Proximity between 5HT secreting enteroendocrine cells and lymphocytes in the gut mucosa of rhesus macaques (Macaca mulatta) is suggesting a role for entrochromaffin cell 5-HT in mucosal immunity. J Neuroimmunol. 2004;146:46-49.
40. Gershon MD. Plasticity of serotonin control mechanisms in the gut. Curr Opin Pharmacol. 2003;3:600-607.
41. Kelum J, Albuqeque FC, Stoner MC, Harris RP. Stroking human jejunal mucosa induces 5-HT release an Cl-secretion via afferent neurons an 5-HT4 receptor. Am J Physiol. 1999;277:G515-G520.
42. Walsh JH. Gastrointestinal hormones. In: Johanson LR, ed. Physiology of the gastrointestinal tract, 3rd edn. New York: Raven Press; 1994:1-128.
43. Goumain M, Voisin T, Lorinet AM, et al. The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning. Mol Pharmacol. 2001;60:124-134.
44. Souli A, Chariot J, Voisin T, et al. Several receptors mediate the antisecretory effect of peptide YY, neuropeptide YY, and pancreatic polypeptide on VIP-induced fluid secretion in the rat jejenum in vivo. Peptides. 1997;18:551-557.
45. Whang EE, Hines OJ, Reeve JR, et al. Anti-secretory mechanisms of peptide YY in rat distal colon. Dig Dis Sci. 1997;42: 1121-1127.
46. Moriya R, Shirakura T, Hirose H, Kanno T, Suzuki J, Kanatani A. NPY Y2 receptor agonist PYY (3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice. Peptides. 2010;31:671-675.